Free Trial

Brokerages Set Natera, Inc. (NASDAQ:NTRA) Price Target at $178.12

Natera logo with Medical background
Remove Ads

Shares of Natera, Inc. (NASDAQ:NTRA - Get Free Report) have received a consensus recommendation of "Buy" from the sixteen ratings firms that are currently covering the stock, MarketBeat reports. Sixteen research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $178.12.

Several analysts recently issued reports on NTRA shares. Morgan Stanley increased their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. The Goldman Sachs Group raised their target price on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Finally, Sanford C. Bernstein lifted their price target on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th.

Get Our Latest Stock Analysis on NTRA

Natera Price Performance

NASDAQ:NTRA traded up $5.71 during trading hours on Friday, hitting $148.22. 1,653,873 shares of the stock traded hands, compared to its average volume of 1,342,627. The company has a market cap of $20.04 billion, a price-to-earnings ratio of -84.22 and a beta of 1.80. Natera has a 1 year low of $83.13 and a 1 year high of $183.00. The stock has a 50 day moving average price of $163.70 and a 200 day moving average price of $148.83. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Sell-side analysts forecast that Natera will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 78,553 shares of the business's stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total value of $590,760.00. Following the sale, the director now directly owns 9,704 shares in the company, valued at $1,433,183.76. This trade represents a 29.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 298,946 shares of company stock valued at $47,803,462. Insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after buying an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after buying an additional 2,036,396 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock worth $355,493,000 after purchasing an additional 1,883,481 shares during the period. Norges Bank acquired a new stake in Natera during the fourth quarter valued at $224,040,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Natera in the 4th quarter valued at about $146,419,000. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

(Get Free Report

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Stories

Analyst Recommendations for Natera (NASDAQ:NTRA)

Should You Invest $1,000 in Natera Right Now?

Before you consider Natera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.

While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads